title: [The application of laferon in a combined therapy of purulent cholangitis].
abstract: Results of treatment of 160 patients, operated on for nontumoral biliary ducts impassibility, complicated by purulent cholangitis, were analyzed. In 60 patients intraoperatively and after the operation in complex of treatment laferon solution was injected into biliary ducts in dosage 500,000--1 million IU a day, permitting to reduce the frequency of the postoperative complications occurrence from 62.2 to 36% and of postoperative mortality--from 13 to 6%. Regional immune therapy using laferon stimulates the factors of organism inflammatory reaction and hepatocytes functional state restoration.
authors.forename: V M
authors.initials: VM
authors.lastname: Kopchak
authors.forename: I M
authors.initials: IM
authors.lastname: Todurov
authors.forename: A A
authors.initials: AA
authors.lastname: Stasenko
authors.forename: A I
authors.initials: AI
authors.lastname: Dronov
authors.forename: I V
authors.initials: IV
authors.lastname: Khomiak
authors.forename: V P
authors.initials: VP
authors.lastname: Serdiuk
authors.forename: A V
authors.initials: AV
authors.lastname: Gusev
mesh_terms: D002761:Cholangitis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D042882:Gallstones / Q000150:complications / Q000601:surgery; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D016898:Interferon-alpha; D007430:Intraoperative Care; D011994:Recombinant Proteins
chemical_list: D007370:Interferon Type I; D016898:Interferon-alpha; D011994:Recombinant Proteins; C076799:interferon-alpha 8